tbuckley/cabot-search huggingface dataset:
TEMPORAL AND GEOGRAPHICAL PATTERNS OF ISCHEMIC HEART DISEASE ATTRIBUTABLE TO PARTICULATE MATTER POLLUTION: A GLOBAL COMPREHENSIVE ANALYSIS FROM 1990 TO 2021
Authors: Breeha Saeed, Anusha Parisapogu, Vinay Kumar Gadamidi, Nmair Alziadin, Paritaben Bhalodia, Anjani Thota, Parth Vikram Singh, Juveriya Yasmeen, Rutvij Patel, Hassaan Imtiaz, Hardik Dineshbhai Desai
Journal: Journal of the American College of Cardiology (2025)
IMPACT OF SOCIAL VULNERABILITY ON CORONARY ARTERY DISEASE HOSPITALIZATIONS AMONG MEDICARE BENEFICIARIES IN THE UNITED STATES
Authors: Chukwuemeka Christian Aghasili, Reuben Laryea Odai, Karldon Nwaezeapu, Godbless Ebruvwiyor Ajenaghughrure, Desmond Seshie, Smith Frimpong, Martin E. Matsumura
Journal: Journal of the American College of Cardiology (2025)
PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION
Authors: David J. Schneider, Sean Robert McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Brett Wanamaker, Homam Ibrahim, Mark B. Effron, Patrick Kennedy Hohl, Timothy Alan Shapiro, Kevin M. Ball, Peter M. DiBattiste
Journal: Journal of the American College of Cardiology (2025)
METABOLIC CHARACTERIZATION OF CHRONIC CORONARY ARTERY DISEASE IN THE ISCHEMIA TRIAL
Authors: Stephen Fatuzzo, Matthew Muller, Lars Wallentin, Claes Held, Iftikhar J. Kullo, Bruce M. McManus, L. Kristin Newby, Sripal Bangalore, Harmony R. Reynolds, David Joel Maron, Judith S. Hochman, Jeffrey S. Berger, Jonathan D. Newman, Kelly Ruggles
Journal: Journal of the American College of Cardiology (2025)
PROGNOSTIC IMPACT OF COMBINED PERI-PROCEDURAL INFLAMMATORY MARKERS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Francesca Maria Di Muro, Samantha Sartori, Birgit Vogel, Angelo Oliva, Kenneth Smith, Benjamin Bay, Prakash Krishnan, Mauro Gitto, Joseph Michael Sweeny, Pedro R. Moreno, Johny Nicolas, Nikito Gurung, Michael Gao, George D. Dangas, Annapoorna Subhash Kini, Samin K. Sharma, Roxana Mehran
Journal: Journal of the American College of Cardiology (2025)
MICROVASCULAR RESISTANCE RESERVE COMPARED WITH CORONARY FLOW RESERVE AS AN ADDITIONAL INDEX TO CHARACTERIZE CORONARY MICROVASCULAR DYSFUNCTION
Authors: Ayesha Mirza, Fazal Dalal, Jose E. Exaire, Timothy A. Mixon, Yuvaraj Darren Kumar, Karim Al-Azizi, Srinivasa P. Potluri, Robert Jay Widmer
Journal: Journal of the American College of Cardiology (2025)
TRIGLYCERIDE-GLUCOSE INDEX AS A PREDICTOR OF ADVERSE CARDIOVASCULAR EVENTS IN A CONTEMPORARY UNITED STATES POPULATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Francesca Maria Di Muro, Mark Shneyderman, Birgit Vogel, samantha sartori, Mauro Gitto, Kenneth Smith, Benjamin Bay, Prakash Krishnan, Angelo Oliva, Joseph Michael Sweeny, Pedro R. Moreno, Johny Nicolas, Parasuram Melarcode Krishnamoorthy, Deepak Bhatt, George D. Dangas, Annapoorna Subhash Kini, Samin K. Sharma, Roxana Mehran
Journal: Journal of the American College of Cardiology (2025)
THE ROLE OF GUT MICROBIOME IN CORONARY ARTERY DISEASE: A TAXONOMIC LEVEL METAANALYSIS OF MENDELIAN RANDOMIZATION STUDIES FOCUSING ON FIRMICUTES
Authors: Pooja Suchday, Aashna Ashish Gandhi, Tunisha Shital Shingala, Roohdeep Ghumman, Parth Adrejiya, Mohammad Abubaker, kesar prajapati, Anushka Dhabuwala, Adil Sarvar Mohammed, Priyatham Gurram, Ihsan Al-sabbagh, Rupak Desai
Journal: Journal of the American College of Cardiology (2025)
Attitudes of healthcare professionals and researchers toward wearable and app derived patient generated health data
Authors: Stefanie Brückner, Olamide Sadare, Sabrina Fesl, Madlen Scheibe, Caroline Lang, Stephen Gilbert
Journal: npj Digital Medicine (2025)

Abstract Patient-generated health data (PGHD) from apps and wearables hold significant potential for enhancing personalised care and medical research. Healthcare professionals (HCPs) are key to its successful adoption, as their attitudes can either support or hinder its integration into clinical practice. This review systematically analysed studies on HCPs’ and researchers’ perspectives on PGHD for clinical and research use. Three databases were searched for articles published between January 2013 and April 2023. Of 246 articles screened, 33 met the inclusion criteria. While most participants viewed PGHD positively, concerns around data security, reliability, and workflow integration persist. Addressing these barriers is essential to maximising PGHD’s benefits for participatory medicine and improved clinical outcomes. The included studies presented medium methodological quality, particularly among quantitative and mixed methods with risks of sampling and nonresponse bias, and often low sample sizes in qualitative studies. However, recurring themes across studies allow a valuable interpretation of the findings.
ANTICOAGULATION FOR NEW-ONSET ATRIAL FIBRILLATION/ FLUTTER FOLLOWING SURGICAL LEFT ATRIAL APPENDAGE OCCLUSION WITH CABG
Authors: Vivek Bhat, Bharat Rawlley, Preet Doshi, Waasay Khan, Karthikk Murali, Subaina Naeem Khalid, Pratyaksh Vaishnav, Debanik Chaudhuri
Journal: Journal of the American College of Cardiology (2025)
OPTIMAL PACING FOR CEREBRAL PERFUSION: ELUCIDATING RELATIONSHIP BETWEEN PACEMAKER HEART RATE AND PULSE PRESSURE
Authors: Muhtashim Mian, Ahmed Moustafa, Pavel Antiperovitch, Peter Leong-Sit, Lorne J. Gula, Raymond Yee, Anthony S.L. Tang, habib khan
Journal: Journal of the American College of Cardiology (2025)
Effects of Prothrombin on Podocytopathy and Proteinuria in Glomerular Disease
Authors: Amanda P. Waller, Katelyn J. Wolfgang, Iva Pruner, Zachary S. Stevenson, Eman Abdelghani, Kaushik Muralidharan, Tasha K. Wilkie, Angela R. Blissett, Edward P. Calomeni, Tatyana A. Vetter, Sergey V. Brodsky, William E. Smoyer, Marvin T. Nieman, Bryce A. Kerlin
Journal: Journal of the American Society of Nephrology (2025)

Background Chronic kidney disease (CKD) is a leading cause of death, its progression is driven by glomerular podocyte injury and loss, manifesting as proteinuria. Proteinuria includes loss of coagulation zymogens, cofactors, and inhibitors resulting in a hypercoagulable state characterized by enhanced thrombin generation. Both CKD and proteinuria significantly increase the risk of thromboembolic disease. Meanwhile, anticoagulant medications (which antagonize thrombin and thereby prevent thromboembolism) have been shown to reduce proteinuria in rats and thrombin has been shown to injure cultured human and rat podocytes. We thus aimed to directly determine the influence of circulating prothrombin, the zymogen precursor of thrombin, on glomerular pathobiology. We hypothesized that (pro)thrombin drives podocytopathy, podocytopenia, and proteinuria. Methods Glomerular proteinuria was induced with puromycin aminonucleoside in rats. Prothrombin was either knocked down using an antisense oligonucleotide targeting prothrombin mRNA or elevated by serial intravenous prothrombin protein infusions, previously established methods to model hypo- and hyper-prothrombinemia, respectively. After 10 days plasma prothrombin levels were determined, kidneys were examined for (pro)thrombin co-localization to podocytes, histology, and electron microscopy. Podocytopathy, podocytopenia, proteinuria, and plasma albumin were measured. Results Antisense oligonucleotide-mediated prothrombin knockdown significantly reduced prothrombin colocalization to podocytes, tubular injury, podocyte foot process effacement, podocytopathy, and proteinuria along with improved plasma albumin in the puromycin aminonucleoside glomerular disease model. In contrast, elevated prothrombin levels significantly increased podocytopathy and proteinuria. Podocytopenia was significantly improved in hypo-prothrombinemic vs. hyper-prothrombinemic rats. Conclusions Thrombin generation is enhanced by glomerular proteinuria and thrombin injures conditionally immortalized podocytes in vitro . In the present study, prothrombin knockdown ameliorated in vivo podocyte injury and improved podocyte function in the rat puromycin aminonucleoside-induced glomerular disease model whereas hyper-prothrombinemia exacerbated podocyte injury and diminished podocyte function.
Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification
Authors: Augusto Cama-Olivares, Chloe Braun, Tomonori Takeuchi, Emma C. O'Hagan, Kathryn A. Kaiser, Lama Ghazi, Jin Chen, Lui G. Forni, Sandra L. Kane-Gill, Marlies Ostermann, Benjamin Shickel, Jacob Ninan, Javier A. Neyra
Journal: Journal of the American Society of Nephrology (2025)

Background: Artificial Intelligence (AI) through machine learning (ML) models appears to provide accurate and precise acute kidney injury (AKI) risk classification in some clinical settings, but their performance and implementation in real-world settings has not been established. Methods: PubMed, EMBASE, Web of Science, and Scopus were searched until August 2023. Articles reporting on externally validated models for prediction of AKI onset, AKI severity, and post-AKI complications in hospitalized adult and pediatric patients were searched using text words related to AKI, AI, and ML. Two independent reviewers screened article titles, abstracts, and full texts. Areas under the receiver operating characteristic curves (AUCs) were used to compare model discrimination and pooled using a random-effects model. Results: Of the 4816 articles initially identified and screened, 95 were included representing 3.8 million admissions. The KDIGO-AKI criteria were the most frequently used to define AKI (72%). We identified 302 models, with the most common being logistic regression (37%), neural networks (10%), random forest (9%), and XGBoost (9%). The most frequently reported predictors of hospitalized incident AKI were age, sex, diabetes, serum creatinine, and hemoglobin. The pooled AUCs for AKI onset were 0.82 (95% CI, 0.80-0.84) and 0.78 (95% CI, 0.76-0.80) for internal and external validation, respectively. Pooled AUCs across multiple clinical settings, AKI severities, and post-AKI complications ranged from 0.78 to 0.87 for internal validation and 0.73 to 0.84 for external validation. Although data were limited, results in the pediatric population aligned with those observed in adults. Between-study heterogeneity was high for all outcomes (I 2 &gt;90%), and most studies presented high-risk of bias (86%) according to the Prediction model Risk Of Bias ASsessment Tool. Conclusions: Most externally validated models performed well in predicting AKI onset, AKI severity, and post-AKI complications in hospitalized adult and pediatric populations. However, heterogeneity in clinical settings, study populations, and predictors limits their generalizability and implementation at the bedside.
DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms
Authors: Maxime Schmitt, Hanibal Bohnenberger, Detlef Klaus Bartsch, Daniel-Christoph Wagner, Anne-Sophie Litmeyer, Albert Grass, Anja Rinke, Christine Koch, Marcus Kremer, Matthias Evert, Bruno Märkl, Alexander Quaas, Markus Eckstein, Konrad Steinestel, Carsten Denkert, Katja Steiger, Günter Klöppel, Atsuko Kasajima, Markus Tschurtschenthaler, Sebastian Foersch, Moritz Jesinghaus
Journal: Endocrine Pathology (2025)
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation
Authors: Joseph C. Ahn, Wee Han Ng, Yee Hui Yeo, Hyun-Seok Kim, Yun Wang, Hirsh Trivedi, Walid S. Ayoub, Alexander Kuo, Nicole Rich, Neehar D. Parikh, Ghassan K. Abou-Alfa, Kevin Sheng-Kai Ma, Amit G. Singal, Ju Dong Yang
Journal: Hepatology (2025)

Background &amp; Aims: Immunotherapy has emerged as an effective treatment for advanced hepatocellular carcinoma (HCC). We aimed to investigate the real-world effectiveness of immunotherapy compared to lenvatinib in HCC. Approach &amp; Result: From the TriNetX database, we used a target trial emulation framework and identified HCC patients who received first-line treatment with immunotherapy (atezolizumab/bevacizumab or tremelimumab/durvalumab) or lenvatinib between or between August 2018 and December 2023. Overall survival (OS) was compared using Kaplan-Meier analysis and Cox proportional hazards regression. After propensity score matching, 1203 patients were included in each group. Immunotherapy was associated with improved OS versus lenvatinib (median survival: 545 vs. 425 d; hazard ratio [HR]: 0.86, 95% confidence interval [CI]: 0.76-0.97). Regarding treatment type, atezolizumab plus bevacizumab showed improved survival compared to lenvatinib (n=1070 in each group; HR: 0.87, 95% CI: 0.77-0.99), while the point estimate favored durvalumab plus tremelimumab vs. lenvatinib (HR: 0.81, 95% CI: 0.59-1.12), though this difference was not statistically significant, likely due to small sample size. Regarding etiology, immunotherapy had improved OS compared to lenvatinib in viral hepatitis (n=510 in each group; HR: 0.74, 95% CI: 0.61-0.89) and alcoholic liver disease (n=190 in each group; HR: 0.65, 95% CI: 0.49-0.87), but not in metabolic dysfunction-associated steatotic liver diseases (n=156 in each group; HR: 0.96, 95% CI: 0.70-1.31). Conclusions: In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC.
A DANGEROUS BREW: HOW ENERGY DRINKS CAN UNLEASH LIFE-THREATENING CARDIAC STORMS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS
Authors: Pallavi Matai, Seema Sharma Gautam, Sulochana Khadka, Ashwin Mahesh, Anas Atrash, Gabriela Michelle Calderon Barahona
Journal: Journal of the American College of Cardiology (2025)
Spatiotemporal calcium dynamics orchestrate oligodendrocyte development and myelination
Authors: Jiaxing Li, Frederic Fiore, Kelly R Monk, Amit Agarwal
Journal: Trends in Neurosciences (2025)

Oligodendrocyte lineage cells (OLCs), comprising oligodendrocyte precursor cells (OPCs) and oligodendrocytes, are pivotal in sculpting central nervous system (CNS) architecture and function. OPCs mature into oligodendrocytes, which enwrap axons with myelin sheaths that are critical for enhancing neural transmission. Notably, OLCs actively respond to neuronal activity, modulating neural circuit functions. Understanding neuron-OLC interactions is key to unraveling how OLCs contribute to CNS health and pathology. This review highlights insights from zebrafish and mouse models, revealing how synaptic and extrasynaptic pathways converge to shape spatiotemporal calcium (Ca2+) dynamics within OLCs. We explore how Ca2+ signal integration across spatial and temporal scales acts as a master regulator of OLC fate determination and myelin plasticity.
Epigenetic and metabolic regulation of developmental timing in neocortex evolution
Authors: Matilde Aquilino, Nora Ditzer, Takashi Namba, Mareike Albert
Journal: Trends in Neurosciences (2025)

The human brain is characterized by impressive cognitive abilities. The neocortex is the seat of higher cognition, and neocortex expansion is a hallmark of human evolution. While developmental programs are similar in different species, the timing of developmental transitions and the capacity of neural progenitor cells (NPCs) to proliferate differ, contributing to the increased production of neurons during human cortical development. Here, we review the epigenetic regulation of developmental transitions during corticogenesis, focusing mostly on humans while building on knowledge from studies in mice. We discuss metabolic-epigenetic interplay as a potential mechanism to integrate extracellular signals into neural chromatin. Moreover, we synthesize current understanding of how epigenetic and metabolic deregulation can cause neurodevelopmental disorders. Finally, we outline how developmental timing can be investigated using brain organoid models.
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials
Authors: P. J. Bröckelmann, H. Müller, M. Fuchs, S. Gillessen, D. A. Eichenauer, S. Borchmann, A. S. Robertz, K. Behringer, J. Welters, J. Ferdinandus, B. Böll, H. Tharmaseelan, X. Yang, C. Kobe, H. T. Eich, C. Baues, W. Klapper, P. Borchmann, B. von Tresckow
Journal: Leukemia (2025)
Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency
Authors: Stefan D. Anker, Mahir Karakas, Robert J. Mentz, Piotr Ponikowski, Javed Butler, Muhammad Shahzeb Khan, Khawaja M. Talha, Paul R. Kalra, Adrian F. Hernandez, Hillary Mulder, Frank W. Rockhold, Marius Placzek, Christian Röver, John G. F. Cleland, Tim Friede
Journal: Nature Medicine (2025)
Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial
Authors: Job J. Herrmann, Hans-Peter Brunner-La Rocca, Lisette E. H. J. M. Baltussen, Fabienne Beckers-Wesche, Sebastiaan C. A. M. Bekkers, Louise Bellersen, J. W. Martijn van Eck, H. Carlijne Hassing, Tiny Jaarsma, Gerard C. M. Linssen, Ron Pisters, Sandra Sanders-van Wijk, Marjolein H. I. Verdijk, M. Louis Handoko, Peter van der Meer, Frederik H. Verbrugge, James L. Januzzi, Antoni Bayés-Genís, Robby Nieuwlaat, Laura Rodwell, D. H. Frank Gommans, Roland R. J. van Kimmenade
Journal: Nature Medicine (2025)
Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial
Authors: Tetsuya Kawahara, Tetsuya Inazu, Shoichi Mizuno, Naoki Tominaga, Mikio Toda, Nagahiro Toyama, Chie Kawahara, Gen Suzuki
Journal: Metabolism (2025)
Iron Deficiency in Adults
Authors: Michael Auerbach, Thomas G. DeLoughery, Jennifer S. Tirnauer
Journal: JAMA (2025)

Absolute iron deficiency, defined as low iron stores with or without anemia, affects approximately 2 billion people worldwide and 14% of adults in the US. Iron-deficiency anemia, defined as low hemoglobin due to low iron stores, affects approximately 1.2 billion people worldwide, including 10 million in the US. Absolute iron deficiency progresses from low iron stores to iron-deficiency anemia. Individuals with nonanemic iron deficiency or iron-deficiency anemia may be asymptomatic or experience fatigue, irritability, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspnea, lightheadedness, exercise intolerance, and worsening heart failure (HF). Symptom prevalences vary depending on age, comorbidities (eg, chronic kidney disease [CKD], HF), and severity and rate of development of iron deficiency. The most common causes of iron deficiency are bleeding (menstrual, gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical procedures), inadequate dietary iron intake, and pregnancy. In high-income countries, approximately 38% of nonpregnant, reproductive-age women have iron deficiency without anemia and about 13% have iron-deficiency anemia. During the third trimester of pregnancy, iron deficiency affects up to 84% of pregnant women, based on data from high-income countries. Additional risk factors include use of nonsteroidal anti-inflammatory drugs, inflammatory bowel disease (IBD [13%-90%]), and other chronic inflammatory conditions, such as CKD (24%-85%), HF (37%-61%), and cancer (18%-82%). Testing for iron deficiency is indicated for patients with anemia and/or symptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for those with risk factors such as heavy menstrual bleeding, pregnancy, or IBD. Iron deficiency is diagnosed by low serum ferritin (typically <30 ng/mL) in individuals without inflammatory conditions or by transferrin saturation (iron/total iron binding capacity × 100) less than 20%. Causes of iron deficiency should be identified and treated. Oral iron (ferrous sulfate 325 mg/d or on alternate days) is typically first-line therapy. Intravenous iron is indicated for patients with oral iron intolerance, poor absorption (celiac disease, post-bariatric surgical procedure), chronic inflammatory conditions (CKD, HF, IBD, cancer), ongoing blood loss, and during the second and third trimesters of pregnancy. Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or transferrin saturation are required for diagnosis and screening. Oral iron is first-line therapy for most patients. Intravenous iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.
DECIPHERING COMPLEXITY: A CASE OF MECHANICAL HEMOLYSIS IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WITH CONCURRENT VITAMIN B12 DEFICIENCY
Authors: Thirumala Keerthi Chandrika Kammaripalle, Amulya Gade, Humza Rana, Pawel Borkowski, Sai Priya Kandukoori
Journal: Journal of the American College of Cardiology (2025)
A HIDDEN THREAT: ISOLATED CARDIAC SARCOIDOSIS IN THE ABSENCE OF SYSTEMIC INVOLVEMENT
Authors: Kevin Watat, Majid Yavari, Georgette Nader, Liza Shaban, Rand Sabanci, Moiz Saeed, Adolfo Martinez, Gabriel Panama, Zan Siddiqi, Qi Xuan Ang, Andrew G. Kim, Waleed Shaker, Rohan Kumar, Lalitsiri Atti, FNU Parul, Karuna Rayamajhi, Michael Kehdi
Journal: Journal of the American College of Cardiology (2025)